Subsidiary - healthylife7.com

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare

By healthylife7July 22, 20260

Ten billion dollars. That is what Vertex Pharmaceuticals (Nasdaq: VRTX) agreed to pay on July 6, 2026, to acquire Crinetics Pharmaceuticals (Nasdaq: CRNX) at $85.00 per share, roughly a 101% premium to the prior close

What's Hot

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare

The Power Of Little Treats: Why You Should Spend $5 On Joy This Week

Statins Linked to Lower HCC, Hepatic Decompensation Risk in Chronic Liver Disease

Browsing: Subsidiary

Treasure Global’s Subsidiary Tadaa Capital Acquires Cigar Secret to Develop an AI-Power Premium Lifestyle Membership Ecosystem

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare

The Power Of Little Treats: Why You Should Spend $5 On Joy This Week

Statins Linked to Lower HCC, Hepatic Decompensation Risk in Chronic Liver Disease

How Obesity Shapes Outcomes in Psoriatic Arthritis

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

What do the Middle Ages tell us about mental health then and now? VCU historian Leigh Ann Craig has answers

Fitness

What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare

The Power Of Little Treats: Why You Should Spend $5 On Joy This Week

Statins Linked to Lower HCC, Hepatic Decompensation Risk in Chronic Liver Disease

Health

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

Subscribe to Updates

What's Hot

Browsing: Subsidiary